Products from BPS Bioscience require a minimum order value above 400€
Applications: Use as a positive control for transductionOptimize transduction assays and track protein expression over time
Description: Adeno-Associated Virus serotype 9 (AAV9) is one of the most promising serotypes for gene therapy applications. AAV9 transduces a wide range of tissue types, including cardiac and skeletal muscle, liver, pancreas, and eye tissue. AAV8 and AAV9 have recently been used to correct disease-causing mutations and improve muscle function in mouse models of Duchenne muscular dystrophy. AAV9 has significantly lower seroprevalence in the human population than other AAV serotypes, making it a desirable candidate for therapeutic applications.These AAV particles constitutively express the firefly (Photinus pyralis) luciferase and enhanced Green Fluorescent Protein (eGFP) genes connected via a T2A linker, under the control of a CMV promoter. The T2A self-cleaving peptide (derived from Thosea asigna virus 2A) leads to the efficient cleavage of the transcript and expression of luciferase and eGFP as two separate proteins.
Formulation: AAV9 was produced in HEK293-AAV cells and is supplied in PBS-MK (PBS Magnesium-Potassium) buffer containing 0.01% Pluronic F68.
Purification: The purity of the AAV particles was confirmed to be greater than 90% by staining with One-Step Lumitein™ UV Protein Gel Stain (Biotium #21005-1L). The purity will vary with each lot; the exact value will be provided with each shipment.
Storage Stability: AAV is shipped with dry ice. For long-term storage, it is recommended to store AAV at -80°C.
Supplied As: Two vials (50 µl x 2) of AAV at a titer ≥1 x 1012 TU/ml. The titer is determined by qPCR and will vary with each lot; the exact value will be provided with each shipment.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
English
Deutsch
